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ABSTRACT Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent for
Kaposi’s sarcoma (KS), which is one of the most common HIV-associated neoplasms. The
endothelium is the thin layer of squamous cells where vascular blood endothelial cells
(BECs) line the interior surface of blood vessels and lymphatic endothelial cells (LECs) are
in direct contact with lymphatic vessels. The KS lesions contain a prominent compart-
ment of neoplastic spindle morphology cells that are closely related to LECs. Further-
more, while KSHV can infect both LECs and BECs in vitro, its infection activates genetic
programming related to lymphatic endothelial cell fate, suggesting that lymphangio-
genic pathways are involved in KSHV infection and malignancy. Here, we report for the
first time that viral interferon regulatory factor 3 (vIRF3) is readily detected in over 40%
of KS lesions and that vIRF3 functions as a proangiogenic factor, inducing hypersprout-
ing formation and abnormal growth in a LEC-specific manner. Mass spectrometry analy-
sis revealed that vIRF3 interacted with histone deacetylase 5 (HDAC5), which is a signal-
responsive regulator for vascular homeostasis. This interaction blocked the
phosphorylation-dependent cytosolic translocation of HDAC5 and ultimately altered
global gene expression in LECs but not in BECs. Consequently, vIRF3 robustly induced
spindle morphology and hypersprouting formation of LECs but not BECs. Finally, KSHV
infection led to the hypersprouting formation of LECs, whereas infection with a ΔvIRF3
mutant did not do so. Collectively, our data indicate that vIRF3 alters global gene ex-
pression and induces a hypersprouting formation in an HDAC5-binding-dependent and
LEC-specific manner, ultimately contributing to KSHV-associated pathogenesis.
IMPORTANCE Several lines of evidences indicate that KSHV infection of LECs in-
duces pathological lymphangiogenesis and that the results resemble KS-like spindle
morphology. However, the underlying molecular mechanism remains unclear. Here,
we demonstrated that KSHV vIRF3 is readily detected in over 40% of various KS le-
sions and functions as a potent prolymphangiogenic factor by blocking the
phosphorylation-dependent cytosolic translocation of HDAC5, which in turn modu-
lates global gene expression in LECs. Consequently, vIRF3-HDAC5 interaction contrib-
utes to virus-induced lymphangiogenesis. The results of this study suggest that
KSHV vIRF3 plays a crucial role in KSHV-induced malignancy.
KEYWORDS Kaposi’s sarcoma-associated herpesvirus, angiogenesis, histone
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Kaposi’s sarcoma-associated herpesvirus (KSHV) has been identified as an etiologicagent of multicentric Castleman’s disease (MCD), primary effusion lymphoma (PEL),
and Kaposi’s sarcoma (KS) (1–3). KS is a neoplasia of lymphatic endothelial origins that
is characterized by a prominent compartment of spindle cells (SCs), which harbor
mainly latent KSHV (4, 5). Furthermore, previous studies showed that KSHV infection
activates genetic programming related to lymphatic endothelial cell (LEC) fate, sug-
gesting that lymphangiogenic pathways are involved in KSHV infection and malignancy
(6–8). Mounting data show that overexpression of several KSHV genes directly induces
a number of angiogenic and/or lymphangiogenic pathways (7, 9). Even though accu-
mulated studies suggest that LECs rather than vascular blood endothelial cells (BECs)
are the primary precursors of KS, the mechanism by which KSHV induces lymphatic
growth pathways remains unclear.
Angiogenesis, the process of formation of new blood vessels from preexisting ones,
is a physiological and pathological process that initiates from quiescent endothelium
being activated by proangiogenic stimuli (10, 11). Once activated, endothelial cells
migrate and form sprouts that are involved in characteristic changes of the gene
expression profile. Recently, histone deacetylase 5 (HDAC5), a member of the class
IIa HDACs, has emerged as a crucial signal-responsive regulator of gene expression
involved in vascular homeostasis (12–15). Remarkably, unlike other HDAC families, class
IIa HDACs lack measurable enzymatic activity (14). Thus, in order to regulate expression
of their target genes, members of the class IIa HDACs utilize signaling-dependent
nucleocytoplasmic shuttling (15, 16). For instance, upon stress, HDAC5 can be phos-
phorylated and translocated to the cytoplasm; this ultimately leads to anti-angiogenic
gene expression, suggesting that HDAC5 is a crucial proangiogenic factor in the
endothelium (12, 17).
The KSHV genome encodes four types of viral interferon regulatory factors (vIRFs),
vIRF1 to vIRF4, which are homologous to cellular IRFs, which are clustered within one
genomic locus (18–20). Although all vIRFs inhibit both host interferon response and
control cellular growth, differences in their activation characteristics result in distinct
immune evasion strategies. This enables efficient lifelong persistence and facilitates the
development of KSHV-associated malignancy. Expression of vIRF3 is required for con-
tinuous proliferation of PEL cells (21) and causes dramatic changes in critical host
pathways such as apoptosis, cell cycle, antiviral immune response, and tumorigenesis
(9, 18–20). It was previously shown that vIRF3 (also referred to as LANA-2) is constitu-
tively expressed in B cell lymphotropic diseases, PEL, and MCD but not in KS tumors
(22). Taken together, these findings indicate that vIRF3 is a crucial factor for mainte-
nance of KSHV-associated lymphoproliferative disease. Nevertheless, the biological
function of vIRF3 in KS is not clear.
In the present study, we found that KSHV vIRF3 was readily detected in over 40% of
KS lesions and that it interacted directly with HDAC5, leading to the decreased
phosphorylation of HDAC5 and retention of HDAC5 activity in the nucleus. Conse-
quently, vIRF3 expression altered global gene expression of LECs and facilitated hyper-
sprouting formation in LECs. Collectively, our results demonstrate the crucial role of
vIRF3 as a driving force in KSHV-associated pathogenesis.
RESULTS
KSHV vIRF3 is expressed in KS lesions. Among the vIRFs, vIRF3 is latently expressed
and required for the proliferation of virus-induced B cell lymphoma (18, 21, 22).
However, it is unclear whether vIRF3 is expressed in KS lesions. To elucidate the
expression of vIRF3 in KS, we performed tissue microarray (TMA) analysis of KS tissue
samples, consisting of 11 normal biopsy specimens and 50 KS biopsy specimens from
various organs, by immunohistochemistry using a CM-A807 mouse monoclonal anti-
body against vIRF3. In contrast to a previous report that vIRF3 is exclusively expressed
in B cell lymphoproliferative diseases, our results showed that vIRF3 was expressed in
~42% of KS tissues from various organs, including skin, lymph node, mouth, head/neck,
tonsil, and rectum KS samples (Fig. 1 and Table 1). In 11 normal tissue specimens, no
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vIRF3 staining was observed. Results obtained using the LANA antibody for KS TMA
corroborated the results obtained using CM-A807 monoclonal antibody (Table 1).
Interestingly, consistent with the nuclear-cytoplasmic shuttling property of vIRF3 (23),
7 of the 21 vIRF3-positive KS specimens showed both nuclear and cytoplasmic staining,
while 14 of the 21 vIRF3-positive specimens were mainly enriched in the nucleus (Fig. 1
and Table 1). This observation shows that vIRF3 is expressed in ~42% of KS tissues from
various organs.
KSHV vIRF3 induces hypersprouting formation in lymphatic endothelial cells
but not in blood endothelial cells. In order to understand the biological function of
vIRF3 in highly angiogenic KS, we first generated E6/E7 immortalized LEC and BEC cell
lines that constitutively expressed vIRF3. To further validate the E6/E7 protein effects on
LECs and BECs, we choose representative unique genes of LECs and BECs and per-
formed real-time PCR (RT-PCR) along with immunoblotting. Notably, without any
change in the characteristics of LECs and BECs, as ascertained by RT-PCR of either LEC-
or BEC-specific markers, vIRF3 induced elongated spindle cell morphology in LECs but
not in BECs (Fig. 2A). Prox1 and podoplanin were used as positive markers for LECs (24)
and CXCR4 and neuropilin-1 were employed as positive markers for BECs (25). To
examine whether vIRF3 has the ability to induce angiogenesis, we performed capillary-
like tube formation assays using BEC-E6/E7-vector, BEC-E6/E7-V5/vIRF3, LEC-E6/E7-
vector, and LEC-E6/E7-V5/vIRF3. We found that at 6 h after seeding the cells onto
matrigel matrix, both BEC-E6/E7-V5/vIRF3 and LEC-E6/E7-V5/vIRF3 readily formed tubes
compared with BEC-E6/E7-vector and LEC-E6/E7-vector (Fig. 2B). We also prepared cell
spheroid assays from BEC-E6/E7-vector, BEC-E6/E7-V5/vIRF3, LEC-E6/E7-vector, and LEC-
E6/E7-V5/vIRF3. vIRF3 actively induced sprouting formation in LECs (Fig. 2C) but not in
BECs (data not shown). These data indicate that KSHV vIRF3 expression leads to
lymphatic endothelial capillary sprouting.
vIRF3 is required for KSHV-mediated transformation of LECs. To examine the
role of vIRF3 during lymphangiogenesis in the context of KSHV, we first generated a
vIRF3 deletion mutant by adding a premature stop codon within vIRF3 exon1 from
BAC16 (KSHV-ΔvIRF3 BAC16) via “scarless” mutagenesis (26). To rule out the possibility
FIG 1 vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen
Resource and performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning.
A biopsy sample of KS TMA was stained with anti-LANA and anti-vIRF3 (CM-A807). Representative images
show the LANA staining of skin KS lesion and the vIRF3 staining of skin, tonsil, and mouth KS lesions and
positive staining corresponding to either LANA or vIRF3 in total KS biopsy specimens embedded in TMA.
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TABLE 1 Immunohistochemistry of vIRF3 expression in KS tissue lesionsa
Tissue type and
biopsy specimen ID
LANA
(1:500)
vIRF3
(1:750) Organ
Normal
1 No No Lymph node
2 No Lymph node
4 No No Lymph node
31 No Lymph node
42 No Lymph node
55 No No Lymph node
91 No No Lymph node
92 No No Lymph node
93 No No Lymph node
94 No No Lymph node
99 No Lymph node
KS
8 Positive Positive Skin
9 Positive Positive Skin
15 Positive Positive Skin
16 Positive
18 Positive Positive Skin
19 No Skin
20 Positive Positive Skin
24 No Positive Mouth
25 No No Mouth
27 No No Lymph node
28 No Positive Lymph node
29 No Lymph node
30 No Lymph node
37 Positive No Skin
38 No Skin
58 Positive Skin
62 No Positive Head/neck
65 Positive No Tonsil
66 Positive Tonsil
67 Positive No Head/neck
73 Positive Lymph node
74 Positive Lymph node
87 Positive Positive Skin
88 Positive Positive Skin
89 Positive Positive Mouth
90 Positive Positive Mouth
95 Positive Positive Mouth
97 No No Lymph node
109 No Tonsil
119 No No Skin
121 No Positive Skin
128 No No Skin
136 No Positive Lymph node
147 No No Mouth
153/167 Positive Positive Mouth (skin)
157 Positive Positive Lymph node
161 Positive No Mouth
162 Positive No Mouth
171 Positive Positive Mouth
172 Positive Positive Tonsil
174 No No Skin
183 No Skin
187 No Mouth
190 No Positive Rectum
195 Positive No Skin
196 Positive No Skin
198 Positive No Skin
200 Positive No Anus
203 No No Skin
215 No No Lymph node
aBlank cells indicate that no tissue was embedded; Positive indicates nuclear staining of vIRF3; Positive
indicates nuclear and cytoplasmic staining of vIRF3. Zero of 11 (0%) and zero of 11 (0%) normal tissue
specimens gave positive or positive results for LANA and vIRF3, respectively; 27 of 50 (54%) and 21 of 50
(42%) KS specimens gave positive or positive results for LANA and vIRF3, respectively. ID, identifier.
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of second-site mutations, we also constructed revertant clones in which the wild-type
(WT) vIRF3 was restored (KSHV-R-ΔvIRF3 BAC16) (Fig. 3A). After verifying the recombi-
nant constructs by DNA sequencing and enzyme digestion performed with NheI and
AseI, we produced infectious virus according to a previously described method (26). We
next determined whether deletion of vIRF3 had an effect on the production of
infectious virus and viral gene expression. To this end, individual progeny viruses
obtained from iSLK cells harboring KSHV-ΔvIRF3 BAC16, KSHV-R-ΔvIRF3 BAC16, and
KSHV-BAC16 were used to infect primary LECs, and infection was quantified by green
fluorescent protein (GFP) analysis. Levels of infection of primary LECs were comparable
between WT and derivative viruses (see Fig. S1 in the supplemental material), suggest-
ing that vIRF3 deletion does not affect virus production and infectivity. The lack of vIRF3
expression from KSHV-ΔvIRF3 BAC16 was confirmed (Fig. 3A, right panel). To further
confirm that the vIRF3 gene is required for KSHV-mediated lymphatic endothelial cell
sprouting, primary LECs were infected with WT, ΔvIRF3, and R-ΔvIRF3 BAC16 KSHV,
followed by a tube formation assay performed on Matrigel. This showed that both WT
and R-ΔvIRF3 KSHV induced capillary-like tube formation of primary LECs, whereas tube
formation was dramatically reduced upon infection of recombinant ΔvIRF3 KSHV
(Fig. 3B). Remarkably, both WT KSHV infection and R-ΔvIRF3 KSHV infection induced
hypersprouting formation of primary LECs, whereas infection with ΔvIRF3 KSHV did not
(Fig. 3C). Taken together, these results demonstrate that vIRF3 plays a critical role in
KSHV-induced lymphatic endothelial cell sprouting.
vIRF3 reduces HDAC5 phosphorylation and thereby maintains the nuclear
location of HDAC5. To decipher the underlying molecular mechanism of vIRF3-induced
FIG 2 vIRF3 expression facilitates sprouting formation in a LEC-specific manner. (A) Induction of spindle morphogenesis by vIRF3 in LECs
but not in BECs (left panel) and real-time RT-PCR measurement of levels of podoplanin, Prox1, Neutropilin-1, and CXCR4 from LEC-E6/E7
and BEC-E6/E7 cells (middle panel). Prox1 expression was detected in LEC-E6/E7 cells (right panel). IB, immunoblot. (B) Tube formation
assay. Either BECs expressing vector and vIRF3 or LECs expressing vector and vIRF3 were tested. The assay was monitored at the indicated
time points. (C) Sprouting formation assay. Assays were performed on matrigel with LEC-E6/E7 vector and LEC-E6/E7 V5/vIRF3.
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hypersprouting formation in LECs, we performed mass spectrometry analysis to identify
vIRF3-associated proteins using tetracycline-inducible V5-tagged vIRF3-expressing cell lines.
TRExBCBL-1 V5/vIRF3 cells were treated with or without doxycycline (Doxy) for 24 h,
followed by immunoprecipitation with an anti-V5 antibody. A polypeptide with a molecular
mass of ~120 kDa was specifically found in Doxy-induced TRExBCBL-1 V5/vIRF3 cells. Mass
spectrometry revealed this polypeptide to be histone deacetylase 5 (HDAC5) (Fig. 4A). We
further confirmed that vIRF3 interacted with endogenous HDAC5 by immunoprecipitation
(Fig. 4B). Previous studies reported that phorbol 12-myristate 13-acetate (PMA) phosphor-
ylates HDAC5 at S259 and S498, leading to its nuclear export (27, 28). Having identified
HDAC5 as a binding partner of vIRF3, we examined whether vIRF3 deregulated the
nucleus-cytoplasm translocation of HDAC5 upon stimulation. To this end, cells were trans-
fected with V5-vIRF3, Flag-HDAC5, or Flag-HDAC5 together with V5-vIRF3, followed by
treatment with PMA to induce the phosphorylation of HDAC5. Confocal analysis showed
that HDAC5 localized in the nucleus in the absence of treatment, while PMA treatment led
to the nuclear export of HDAC5 (Fig. 4C). vIRF3 expression retained HDAC5 in the nucleus
upon PMA treatment (Fig. 4C, arrows). Moreover, upon treatment of TREx/BCBL-1 vector
and TREx/BCBL-1 V5/vIRF3 with Doxy and PMA, we observed a reduction of HDAC5
phosphorylation in vIRF3-expressing cells compared to vector-expressing cells (Fig. 4D).
vIRF3 expression diminished a basal level of HDAC5 phosphorylation at serine 498 in
LEC-V5/vIRF3 cells (Fig. 4E). We also found that HDAC5 was localized in both the nucleus
FIG 3 vIRF3 is required for KSHV-induced tube formation and sprouting formation. (A) (Left panel) Construction of KSHV ΔvIRF3
BAC16. A schematic diagram of KSHV ΔvIRF3 BAC16 construction is shown. (Right panel) Wild-type (WT), ΔvIRF3, and R-ΔvIRF3
recombinant KSHV-infected primary LECs were harvested at 72 h postinfection, and equal amounts of cell lysates were subjected to
SDS-PAGE. (Right panel) Immunoblotting (IB) was performed with the indicated antibodies. (B and C) KSHV-induced tube formation
and sprouting formation. (Left panel) WT, ΔvIRF3, and R-ΔvIRF3 recombinant KSHV-infected primary LECs were placed in Matrigel to
perform sprouting formation and tube formation assays for the indicated times. (Right panel) Total tube lengths formed during the
assay were measured by tube formation ACAS image analysis. *, P  0.05. MOCK indicates KSHV-uninfected primary LECs. (C) Green
fluorescence phase-contrast images of WT, ΔvIRF3, and R-ΔvIRF3 recombinant KSHV-infected primary LECs in matrigel are shown.
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and cytoplasm of LECs, while it was exclusively found in the cytoplasm of BECs. Coexpres-
sion of vIRF3 with HDAC5 resulted in the primarily nuclear localization of HDAC5 in LECs but
not in BECs (Fig. 5). Collectively, these results show that vIRF3 expression significantly
decreases the phosphorylation of HDAC5, retaining HDAC5 in the nucleus.
HDAC5 is required for vIRF3-mediated hypersprouting formation in LECs.
Because vIRF3 interaction deregulated HDAC5 nuclear-cytoplasmic shuttling, we inves-
tigated whether vIRF3 expression also affected HDAC5-mediated gene expression.
RNA-Seq analysis revealed that, consistently with its LEC-specific activity for HDAC5
localization, vIRF3 expression induced large-scale changes in global gene expression
only in LECs but not BECs (Fig. 6A, left panel). Using a cutoff false-discovery-rate (q)
value of 0.05 and a fold change value of 4, we found 1,264 and 1,213 genes that
were up- and downregulated by vIRF3 expression in LECs, respectively (Fig. 6A, right
panel). In contrast, only 40 and 112 genes, respectively, were up- and downregulated
by vIRF3 expression in BECs (Fig. 6A, right panel). Gene set enrichment analysis (GSEA)
of these genes identified epithelial-cell-to-mesenchymal-cell transition, UV response,
apical surface, and myogenesis as upregulated pathways in LECs (Fig. 6B; see also
FIG 4 vIRF3-HDAC5 interaction decreases HDAC5 phosphorylation, blocking phosphorylation-dependent HDAC5 translocation. (A) Silver-stained purified
V5-labeled vIRF3 complexes at 48 h after Doxy treatment of tetracycline-inducible V5-vIRF3-expressing cell lines. Asterisk, V5-vIRF3; arrow, HDAC5; IP,
immunoprecipitation. (B) Interaction of vIRF3-HDAC5. Upon stimulation with Doxy (1 g/ml), we performed IP with anti-V5, followed by IB with anti-HDAC5.
(C) Effect of vIRF3 on the localization of HDAC5. HeLa cells were transiently transfected with the indicated constructs. Cells were then treated with PMA (1 M)
for 2 h before immunofluorescence staining was performed. Arrows indicate the cells coexpressing vIRF3 and HDAC5. (D) Effects of vIRF3 expression on the
phosphorylation of HDAC5. At 24 h posttreatment with Doxy (1 g/ml), TREx/BCBL-1 vector and TREx/BCBL-1 V5/vIRF3 cells were also treated with PMA (1 M)
for 2 h before being harvested. Equal amounts of total proteins were analyzed by IB using anti-HDAC5 pS498-specific antibody. (E) vIRF3 effect on HDAC5
phosphorylation in LECs. LEC-vector and LEC-V5/vIRF3 were harvested and IB was performed with anti-HDAC5 pS498-specific antibody along with other
antibodies.
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Table S1 in the supplemental material). Similar analysis in BECs revealed interferon
gamma response, interferon alpha response, KRAS signaling, and inflammatory re-
sponse as downregulated pathways in BECs (Fig. 6C and Table S1). Taken together,
these results indicate noncanonical activities of vIRF3 in LECs, whereas vIRF3 expression
in BECs appears to be mainly involved in IFN-mediated immune responses.
Because vIRF3 interaction retained HDAC5 activity in the nucleus and led to altered
expression of genes in LECs, we also investigated whether vIRF3-induced sprouting forma-
tion was dependent on HDAC5. Small interfering RNA (siRNA)-mediated knockdown of
HDAC5 expression considerably suppressed sprout formation in LEC-V5/vIRF3 (Fig. 6D).
Consistently with this observation, treatment with a class IIa HDAC inhibitor, MC1568, also
robustly reduced sprouting formation of LEC-V5/vIRF3 (Fig. 6E). These results indicated that
vIRF3-induced sprouting formation of LECs is dependent on HDAC5 expression and activity.
DISCUSSION
The principal targets of KSHV infection in KS lesions are elongated spindle cells (SCs)
thought to be of lymphatic endothelial origin (4). Thus, understanding the role of KSHV
in the reprogramming of lymphatic endothelial cells is critical for understanding how
KSHV infection causes KS tumors. However, it remains unclear which of the KSHV genes
directly contribute to virus-induced reprogramming of LECs. Here, we demonstrate that
KSHV vIRF3 is a prolymphangiogenic factor that dramatically alters the global gene
expression of LECs via the deregulation of HDAC5 activity, ultimately inducing sprout-
ing formation of LECs. Furthermore, we report for the first time that vIRF3 is detectable
in approximately 42% of KS tissues from various organs, strongly suggesting a role of
KSHV vIRF3 in KS pathogenesis.
Several studies have suggested that the original precursor of KS was of lymphatic
FIG 5 vIRF3 deregulates HDAC5 localization in LECs but not in BECs. Immunofluorescence staining for
HDAC5 and vIRF3 was performed. BEC or LEC cells stably expressing vector or V5-vIRF3 were fixed and
viewed by confocal microscopy using either anti-HDAC5 (green) or anti-V5 (red) antibodies. Nucleus
(blue) was detected with Topro-3 staining.
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endothelial lineage. First, KS seldom develops in organs lacking a lymphatic system
(29–31). Second, LECs are more susceptible to KSHV infection than BECs (8). Third,
KS-SCs mainly express LEC markers, as opposed to BEC markers, possibly through the
induction of genetic reprogramming upon KSHV infection (6, 8). Recently, Cheng et al.
showed that three-dimensional spheroid culture of KSHV-infected LECs leads to the
induction of capillary sprouts and changes in gene expression profiles, such as
endothelial-cell-to-mesenchymal-cell transition (EMT) markers (32). Consistently with
these reports, evidence has indicated that vIRF3 directly contributes to the develop-
ment of KS-SCs (1). vIRF3 was readily detected in various KS lesions (Fig. 1) (2).
vIRF3-expressing LECs showed elongated spindle morphology, whereas BECs were not
significantly altered by vIRF3 expression (Fig. 2A). Similar results were observed in
KSHV-infected LECs but not in KSHV-infected BECs (3). vIRF3 expression induced
hypersprouting formation in LECs (Fig. 2C). In line with this, KSHV infection led to
hypersprouting formation of LECs, whereas infection with a ΔvIRF3 mutant did not do
so (Fig. 3C) (4). Surprisingly, vIRF3 expression dramatically altered the transcriptome of
LECs, particularly in EMT pathway-related genes (q 0.05 and fold change 4) (Fig. 6A
and B). By contrast, vIRF3 expression in BECs mostly affected IFN pathway genes
(Fig. 6C), suggesting that vIRF3 functions as an immune modulator in BECs.
Histone or protein deacetylases (HDACs) are enzymes with a critical role in diverse
physiological and pathological processes. Mounting evidence shows that class IIa
FIG 6 Alteration of the global gene expression of LECs by vIRF3 and the essential role of HDAC5 for vIRF3-mediated sprouting formation. (A) (Left panel)
Principal component plot of both lymphatic endothelium gene expression and blood endothelium gene expression profiles upon vIRF3 expression. Numbers
in brackets indicate percentages of total variation explained by each principal component (PC). (Right panel) Venn diagram showing the number of significantly
up- and downregulated genes upon vIRF3 expression in LECs and BECs. (B and C) Gene set enrichment analysis (GSEA) of genes significantly up- or
downregulated upon vIRF3 induction in LECs (B) and BECs (C), respectively. Positive normalized enrichment scores (NES) indicate increased pathway activity,
and negative scores indicate decreased pathway activity. (D and E) The essential role of HDAC5 in vIRF3-induced sprouting formation. Phase-contrast images
are shown. (D) LEC-E6/E7 V5/vIRF3 cells were transfected with siRNA as a control (Scramble) or with HDAC5-specific siRNA for 48 h, followed by embedding
into matrigel. NC, negative control. (E) Sprouting of LEC-E6/E7 V5/vIRF3 spheroids treated with 5 M MC1586 (HDAC5 inhibitor).
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HDACs (HDAC4, HDAC5, HDAC6, HDAC7, and HDAC9) are essential factors for the
angiogenic function of endothelial cells. Remarkably, the deacetylase activity of HDAC5
as well as of other class IIa HDACs is distinct from the conventional HDACs in that it
occurs through signaling-dependent nucleocytoplasmic shuttling, which has an ef-
fect on the repression of anti-angiogenic genes in endothelium. Another peculiarity
shared by the class IIa HDACs is that their N-terminal domain has highly conserved
serine residues that undergo signal-dependent phosphorylation, ultimately leading to
their nucleocytoplasmic shuttling. Our study shows that vIRF3 dramatically decreased
HDAC5 phosphorylation, resulting in the retention of HDAC5 in the nucleus in LECs but
not BECs (Fig. 4 and 5). At this point, the molecular mechanism by which vIRF3
interaction differentially regulates the phosphorylation of HDAC5 in LECs and BECs is
not fully understood. It is reported that HDAC5 is phosphorylated by several different
protein kinases (PKs), including protein kinase C (PKC), PKD, and Ca2/calmodulin-
dependent protein kinases (CaMKs) (13, 27, 33, 34). Interestingly, CaMKs lead to HDAC5
phosphorylation in skeletal muscle cells (33), while PKD induces the phosphorylation of
HDAC5 in BECs (34). Therefore, one possibility is that other as-yet-unidentified kinases
may be involved in the vIRF3-mediated reduction of HDAC5 phosphorylation in LECs.
Additional studies will be necessary to determine the specific mode of action with
regard to the vIRF3-HDAC5 interaction in LECs and BECs.
In summary, we have found that vIRF3 recapitulates KSHV-mediated lymphangio-
genesis through the deregulation of HDAC5 activity. Having shown that the inhibition
of HDAC5 activity by a class IIa HDAC inhibitor abolishes vIRF3-mediated sprouting
formation (Fig. 6D and E), our results convincingly connect class IIa HDACs to the
regulation of KSHV-associated pathogenesis. This indicates that the vIRF3-HDAC5 in-
teraction contributes to KSHV-induced lymphangiogenesis, suggesting this interaction
as a potential therapeutic target for KS therapy.
MATERIALS AND METHODS
Cell culture and cell line construction. Tetracycline-inducible TRExBCBL-1 V5/vIRF3 cells, which
harbor the KSHV genome (35), were cultured in RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (P/S) (Gibco-BRL). iSLKBAC16, iSLK-ΔvIRF3BAC16, and iSLK-R-
ΔvIRF3BAC16 cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FBS and 1% P/S. Human primary dermal lymphatic endothelial cells (LECs) and vascular blood
endothelial cells (BECs) were isolated from deidentified neonatal foreskins under an approval of the
University of Southern California Institutional Review Board (principal investigator [PI], Y. K. Hong) (36)
and cultured in a VascuLife endothelial medium complete kit (Lifeline Cell Technology). Primary LECs
and BECs (subjected to fewer than 5 passages) were immortalized with retroviruses (BD Biosciences)
encoding human papillomavirus E6/E7 proteins and selected with 200 g/ml G418. To establish
vIRF3-expressing LECs and BECs, E6/E7 immortalized BECs and LECs were infected with V5/vIRF3-
expressing lentivirus. At 48 h after transduction, cells were selected using puromycin (0.5 g/ml) and
G418 (200 g/ml).
Construction of vIRF3-deficient recombinant KSHV (vIRF3BAC16). The vIRF3-deficient KSHV was
generated by changing amino acid 31 of the TCTGAG coding sequence of vIRF3 to TCTTAG, resulting in
a stop codon. As previously described, mutagenesis was performed in Escherichia coli strain GS1783 by
using “scarless” mutagenesis (26). The vIRF3 stop mutant was generated by amplifying a kanamycin
resistance (Kanr)/I-SecI cassette from the pEP-Kan-S plasmid using the following primers: forward primer
5=-TGACAGGTCAACATGGCGGGACGCAGGCTTACCTGGATTTGCTAGCGTTTATTGTAGGTGCTTTGGaggatgac
gacgataagtagg and reverse primer 5=-CAAAGGATATTTATCAGAGTCCAAAGCACCTACAATAAACGCTAGCA
AATCCAGGTAAGCCTGCGTaaccaattaaccaattctgattag. Uppercase letters indicate KSHV genomic sequences
that were used for homologous recombination, while sequences given in lowercase letters were used to PCR
amplify the Kanr/I-SceI cassette from the pEP-Kan-S plasmid. Newly generated bacterial artificial chromosome
(BAC) DNAs were digested by NheI and AseI restriction enzymes followed by pulsed-field gel electrophoresis
performed with direct sequencing to verify that the clones had not suffered genetic rearrangements in the
BAC16-vIRF3 stop mutant (ΔvIRF3 BAC16) compared with WT-BAC16.
Production and infection of recombinant KSHV BAC16. iSLKBAC16, iSLK-ΔvIRF3BAC16, and iSLK-R-
ΔvIRF3BAC16 cells were treated with doxycycline (1 g/ml) and NaB (1 mM) for 72 h. After virus-containing
supernatant was collected, levels of infectious units were determined by analysis of GFP-positive cells in
each well that was reinfected with progeny virus by serial dilution. The same amounts of virus were used
for infection with LEC-E6/E7 pCDH and LEC-E6/E7 V5/vIRF3 together with Polybrene (8 M). At 72 h
postinfection, the infected cells were evaluated for tube formation or sprouting formation.
Chemicals and antibodies. Various chemicals were purchased from the following manufacturers:
doxycycline (Doxy), NaB, and PMA from Sigma; class IIa HDAC inhibitor (MC1586) from Tocris Bioscience;
and puromycin, hygromycin B, and G418 from Invitrogen. Primary antibodies were purchased from the
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following manufacturers: HDAC5 and HDAC5 (S498) from Abcam, Inc.; LANA (LNA-1) from Advance; vIRF3
(CM-A807) from Novus; and actin and V5 from Sigma.
Immunohistochemistry and immunofluorescence. TMA sections, which were obtained from the
AIDS Cancer Specimen Resource (ACSR) of the National Cancer Institute, were deparaffinized, rehydrated,
and subjected to antigen retrieval by using sodium citrate buffer (pH 6.0). Primary antibodies consisting
of either LANA antibody (1:500) or vIRF3 antibody (CM-A807; 1:750) were used at 4°C overnight, followed
by DAB (3,3=-diaminobenzidine) chromogen for color development (Envision; Dako). Images were
captured using Aperio digital pathology slide scanners (Leica Biosystems). For immunofluorescence, cells
were fixed with 1% paraformaldehyde and permeabilized with 0.2% Triton X-100. Next, cells were
incubated with V5 or Flag antibody at 37°C for 1 h followed by incubation with fluorescein isothiocyanate
(FITC)-labeled donkey anti-mouse IgG or with rhodamine-labeled donkey anti-rabbit IgG at 37°C for 1 h.
To visualize the nucleus, DAPI (4=,6-diamidino-2-phenylindole) was included in the mounting solution.
Lentiviral shRNA knockdown. Short hairpin RNA (shRNA) expression constructs were prepared
using pLKO.1 lentiviral vector. The shRNA target sequences were as follows: 5=-CAGCAUGACCACCUGA
CAA-3= for HDAC5 and 5=-AGCGUGUAGCUAGCAGAGG-3= for scrambled. Production of lentiviruses and
transduction of cells were performed as previously described (37).
Tube formation and sprouting formation assay. Tube formation assays using growth factor-
reduced matrigel (BD Biosciences) were performed according to the manufacturer’s procedures. Quan-
tification of tube formation was performed using a phase-contrast image and tube formation ACAS
image analysis (Ibidi). To perform the sprouting assay, either KSHV-infected LECs or LEC-E6/E7 V5/vIRF3
was placed on 0.5% agarose, embedded into a collagen/Methocel gel (38), and incubated with LEC
culture medium for 2 to 5 days.
RNA purification and RT-qPCR. Total RNA was isolated using TRIzol (Sigma), and reverse transcrip-
tion was done using an iScript cDNA synthesis kit (Bio-Rad). Real-time quantitative PCR (qPCR) analysis
was performed as described previously (37). The sequences of the primers used for RT-qPCR were as
follows: for Prox1, 5= CCGACGCAAGTTGACGGCTCTCGACTA 3= (Forward) and 5= TTGCCTTAAGCATTACC
AGGTAATCAT 3= (Reverse); for LYVE-1, 5= ATGGCCAGGTGCTTCAGCCTGGTGTTG 3= (Forward) and 5=
GTGTTGCAGTTTGAGTGTTGAATATGG 3= (Reverse); for CXCR4, 5= CACTTCAGATAACTACACCG 3= (Forward)
and 5= ATCCAGACGCCAACATAGAC 3= (Reverse); and for neuropilin-1, 5= CAGGTGATGACTTCCAGCTCA 3=
(Forward) and 5= CCCAGTGGCAGAAGGTCTTG 3= (Reverse).
RNA-Seq data analysis. Sequencing libraries were prepared from previously purified RNA using an
Illumina TruSeq Stranded mRNA Library Prep kit following the manufacturer’s instructions. Sequencing
was performed on a NextSeq 500 platform using 175bp chemistry. Sequencing reads were aligned to
the hg19 genome and transcriptome using TopHat v2.1.0 with parameters ’--read-mismatches 2 --read-
gap-length 2 --read-edit-dist 2 --max-multihits 10 --library-type fr-firststrand’. Gene-level quantification
was performed using htseq-count from the HTSeq framework (v0.6.0). Differential expression analysis
was performed using the “DESeq2” R package (version 1.16.1). Results determined for genes with a
Benjamini-Hochberg-adjusted P value of 0.05 and an absolute fold change value greater than 4 were
considered statistically significant. Gene set enrichment analysis (GSEA) was performed using GSEA
software package version 2.1.0 with the hallmark gene sets from Molecular Signatures Database v6.1.
Accession number(s). RNA-Seq data are available at the Gene Expression Omnibus (GEO) database
under accession number GSE102132.
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